This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rushing, P. A. Articles by Woods, S. C. Search for Related Content PubMed PubMed Citation Articles by Rushing, P. A. Articles by Woods, S. C.

Inhibition of Central Amylin Signaling Increases Food Intake and Body Adiposity in Rats

Department of Psychiatry (P.A.R., M.M.H., R.J.S., E.L.A., S.C.W.) and Medicine (D.A.D.), College of Medicine, University of Cincinnati, Cincinnati, OH 45267-0559, USA; and Institute of Veterinary Physiology (T.A.L.), University of Zürich, Winterthurerstrasse 260, CH 8057 Zürich, Switzerland

Address all correspondence and requests for reprints to: Paul A. Rushing, Ph.D., University of Cincinnati, College of Medicine, Department of Psychiatry, P. O. Box 670559, Cincinnati, Ohio 45267-0559.

Amylin is a 37-amino acid peptide hormone that is co-secreted with insulin by pancreatic ß cells in response to feeding. We recently reported that amylin potently reduces food intake, body weight, and adiposity when delivered into the 3^rd cerebral ventricle (i3vt) of rats. We have now infused i3vt a specific antagonist (AC187) to ascertain the physiological relevance of central amylin in the control of energy balance. After establishing the ability of i3vt AC187 to block the anorexic effect of i3vt amylin, we performed an experiment to examine the impact of acute inhibition of central amylin signaling on feeding. Separate groups (n = 7/group) of ad lib-fed male Long Evans rats were given one bolus i3vt infusion of synthetic cerebrospinal fluid vehicle (CSF) or AC187 (250 or 1000 pmol). Acute infusion of AC187 tended to increase 1-h food intake and significantly elevated 4-h intake. Both the 250 and 1000 pmol doses produced significant increases as compared to CSF. In another experiment designed to tonically inhibit central amylin signaling over an extended period, two other groups of rats (n = 6/group) received continuous i3vt infusion of CSF or 100 pmol/h AC187 over 14 days via implantable osmotic pumps. Rats receiving AC187 ate significantly more food over the 14-day infusion period relative to controls (CSF = 322 ± 6 g, AC187 = 360 ± 12 g). Although body weight was not significantly affected, body fat was increased by about 30% in the AC187 rats, with no difference in lean tissue between the groups. Additionally, although fasting plasma glucose did not differ between the CSF and AC187 groups after 14 days of infusion, plasma insulin was significantly elevated in the AC187 rats. In summary, the present results document significant increases of food intake and body adiposity resulting from inhibition of central amylin signaling. They are consistent with our hypothesis that CNS actions of endogenous amylin contribute to the long-term regulation of energy balance.

This article has been cited by other articles:

				J. J. Hwang, J. L. Chan, G. Ntali, D. Malkova, and C. S. Mantzoros Leptin Does Not Directly Regulate the Pancreatic Hormones Amylin and Pancreatic Polypeptide: Interventional studies in humans Diabetes Care, May 1, 2008; 31(5): 945 - 951. [Abstract] [Full Text] [PDF]

				P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1798 - R1808. [Abstract] [Full Text] [PDF]

				C. Mack, J. Wilson, J. Athanacio, J. Reynolds, K. Laugero, S. Guss, C. Vu, J. Roth, and D. Parkes Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1855 - R1863. [Abstract] [Full Text] [PDF]

				S. R. Smith, J. E. Blundell, C. Burns, C. Ellero, B. E. Schroeder, N. C. Kesty, K. S. Chen, A. E. Halseth, C. W. Lush, and C. Weyer Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study Am J Physiol Endocrinol Metab, August 1, 2007; 293(2): E620 - E627. [Abstract] [Full Text] [PDF]

				D. F. Kruger, C. L. Martin, and C. E. Sadler New insights into glucose regulation. The Diabetes Educator, March 1, 2006; 32(2): 221 - 228. [Abstract] [Full Text] [PDF]

				K. J. Pulman, W. M. Fry, G. T. Cottrell, and A. V. Ferguson The Subfornical Organ: A Central Target for Circulating Feeding Signals J. Neurosci., February 15, 2006; 26(7): 2022 - 2030. [Abstract] [Full Text] [PDF]

				M. C. Riddle and D. J. Drucker Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1 Diabetes Care, February 1, 2006; 29(2): 435 - 449. [Full Text] [PDF]

				R. D. Reidelberger, A. C. Haver, U. Arnelo, D. D. Smith, C. S. Schaffert, and J. Permert Amylin receptor blockade stimulates food intake in rats Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2004; 287(3): R568 - R574. [Abstract] [Full Text] [PDF]

				R. L. Hull, G. T. Westermark, P. Westermark, and S. E. Kahn Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3629 - 3643. [Abstract] [Full Text] [PDF]

				S. L. Aronoff, K. Berkowitz, B. Shreiner, and L. Want Glucose Metabolism and Regulation: Beyond Insulin and Glucagon Diabetes Spectr, July 1, 2004; 17(3): 183 - 190. [Abstract] [Full Text] [PDF]

				P. A. Hollander, P. Levy, M. S. Fineman, D. G. Maggs, L. Z. Shen, S. A. Strobel, C. Weyer, and O. G. Kolterman Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-year randomized controlled trial Diabetes Care, March 1, 2003; 26(3): 784 - 790. [Abstract] [Full Text] [PDF]

				F. Whitehouse, D. F. Kruger, M. Fineman, L. Shen, J. A. Ruggles, D. G. Maggs, C. Weyer, and O. G. Kolterman A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes Diabetes Care, April 1, 2002; 25(4): 724 - 730. [Abstract] [Full Text] [PDF]

				R. D. Reidelberger, L. Kelsey, and D. Heimann Effects of amylin-related peptides on food intake, meal patterns, and gastric emptying in rats Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2002; 282(5): R1395 - R1404. [Abstract] [Full Text] [PDF]